Key clinical papers

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood. 2022.
Commentary by Tatjana Stankovic and Marwan Kwok
Institute of Cancer and Genomic Sciences, University of Birmingham, UK